← Back to Screener
Nurix Therapeutics, Inc. Common stock (NRIX)
Price$16.69
Favorite Metrics
Price vs S&P 500 (26W)66.05%
Price vs S&P 500 (4W)6.94%
Market Capitalization$1.75B
All Metrics
Book Value / Share (Quarterly)$4.65
P/TBV (Annual)0.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)29.54%
Cash Flow / Share (Quarterly)$-2.63
Price vs S&P 500 (YTD)-13.19%
Net Profit Margin (TTM)-411.37%
EPS (TTM)$-3.16
10-Day Avg Trading Volume1.38M
EPS Excl Extra (TTM)$-3.16
Revenue Growth (5Y)36.35%
EPS (Annual)$-3.05
ROI (Annual)-49.09%
Net Profit Margin (5Y Avg)-343.51%
Cash / Share (Quarterly)$5.23
Revenue Growth QoQ (YoY)-66.12%
ROA (Last FY)-38.43%
Revenue Growth TTM (YoY)27.23%
EBITD / Share (TTM)$-3.29
ROE (5Y Avg)-50.25%
Operating Margin (TTM)-439.26%
Cash Flow / Share (Annual)$-2.59
P/B Ratio3.65x
P/B Ratio (Quarterly)3.38x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)23.46x
ROA (TTM)-48.44%
EPS Incl Extra (Annual)$-3.05
Current Ratio (Annual)7.02x
Quick Ratio (Quarterly)5.86x
3-Month Avg Trading Volume1.35M
52-Week Price Return72.28%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.82
P/S Ratio (Annual)20.90x
Asset Turnover (Annual)0.12x
52-Week High$22.50
Operating Margin (5Y Avg)-360.87%
EPS Excl Extra (Annual)$-3.05
CapEx CAGR (5Y)25.21%
26-Week Price Return70.04%
Quick Ratio (Annual)6.86x
13-Week Price Return-7.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.01x
Enterprise Value$1,683.602
Revenue / Share Growth (5Y)16.14%
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)-6.64%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-314.00%
Cash / Share (Annual)$5.82
3-Month Return Std Dev49.63%
Net Income / Employee (TTM)$-1
ROE (Last FY)-49.09%
EPS Basic Excl Extra (Annual)$-3.05
P/FCF (TTM)72.80x
Receivables Turnover (TTM)68.62x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)12.88x
ROI (TTM)-64.21%
P/S Ratio (TTM)24.45x
Pretax Margin (5Y Avg)-343.14%
Revenue / Share (Annual)$0.97
Tangible BV / Share (Annual)$6.44
Price vs S&P 500 (52W)42.45%
Year-to-Date Return-10.54%
5-Day Price Return4.50%
EPS Normalized (Annual)$-3.05
ROA (5Y Avg)-35.14%
Net Profit Margin (Annual)-314.90%
Month-to-Date Return9.48%
Cash Flow / Share (TTM)$-2.61
EBITD / Share (Annual)$-3.20
Operating Margin (Annual)-340.16%
ROI (5Y Avg)-50.25%
EPS Basic Excl Extra (TTM)$-3.16
P/TBV (Quarterly)1.29x
P/B Ratio (Annual)3.18x
Pretax Margin (TTM)-410.31%
Book Value / Share (Annual)$5.29
Price vs S&P 500 (13W)-8.36%
Beta1.93x
Revenue / Share (TTM)$0.65
ROE (TTM)-64.21%
52-Week Low$8.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.26
4.30
4.30
4.30
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NRIXNurix Therapeutics, Inc. Common stock | 24.45x | 27.23% | — | — | $16.69 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and inflammatory diseases using an AI-enhanced discovery platform. The company's pipeline includes candidates such as Bexobrutideg and Zelebrudomide that target specific disease-causing proteins in immune and oncology-related pathways.